Endothelial Dysfunction in Resistance Arteries of Hypertensive Humans: Old and New Conspirators

Journal of Cardiovascular Pharmacology

Volumn 67, Issue 6, 2016, Pages 451-457

  Virdis, Agostino ^a   Taddei, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

cyclooxygenase; endothelium; ghrelin; oxidative stress

Indexed keywords

ACETYLCHOLINE; ARACHIDONIC ACID; ASCORBIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ENDOTHELIN; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; GHRELIN; GLYCERYL TRINITRATE; INDOMETACIN; N(G) METHYLARGININE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; SUBSTANCE P; SUPEROXIDE; TAK 044; THROMBOXANE A2; PROSTAGLANDIN;

ANGIOGRAPHY; ARTERIOLE; ARTERY RESISTANCE; CELL ACTIVATION; CORONARY ARTERY BLOOD FLOW; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MICROCIRCULATION; OXIDATIVE STRESS; PATHOGENESIS; PLETHYSMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE CELL; VASOCONSTRICTION; VASODILATATION; VASOMOTOR REFLEX; AGE; HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

AGE FACTORS; CYCLOOXYGENASE 2; ENDOTHELINS; ENDOTHELIUM, VASCULAR; GHRELIN; HUMANS; HYPERTENSION; MICROCIRCULATION; NITRIC OXIDE; PROSTAGLANDINS; REACTIVE OXYGEN SPECIES; VASOCONSTRICTION; VASODILATION;

EID: 84955600346     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000362     Document Type: Review

References (51)

1. Flammer AJ, Anderson T, Celermajer DS, et al. The assessment of endothelial function: from research into clinical practice. Circulation. 2012;126:753-767.
2. Vanhoutte PM, Feletou M, Taddei S. Endothelium-dependent contractions in hypertension. Br J Pharmacol. 2005;144:449-458.
3. Virdis A, Ghiadoni L, Taddei S. Human endothelial dysfunction: Edcfs. Pflugers Arch. 2010;459:1015-1023.
4. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005;111:363-368.
5. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part i: methodological issues for assessment in the different vascular beds: a statement by the working group on endothelin and endothelial factors of the european society of hypertension. J Hypertens. 2005;23:7-17.
6. Virdis A, Ghiadoni L, Versari D, et al. Endothelial function assessment in complicated hypertension. Curr Pharm Des. 2008;14: 1761-1770.
7. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force. J Am Coll Cardiol. 2002;39:257-265.
8. Goodhart DM, Anderson TJ. Role of nitric oxide in coronary arterial vasomotion and the influence of coronary atherosclerosis and its risks. Am J Cardiol. 1998;82:1034-1039.
9. Egashira K, Suzuki S, Hirooka Y, et al. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance p. Hypertension. 1995;25:201-206.
10. Marzilli M, Taddei S, Virdis A, et al. Endothelial function and coronary microcirculaiton in essential hypertension. J Hypertens. 1998;16 (suppl 8):S59-S63.
11. Virdis A, Neves MF, Duranti E, et al. Microvascular endothelial dysfunction in obesity and hypertension. Curr Pharm Des. 2013;19: 2382-2389.
12. Versari D, Daghini E, Virdis A, et al. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol. 2009;157:527-536.
13. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001;104:2673-2678.
14. Mulvany MJ, Baumbach GL, Aalkjaer C, et al. Vascular remodeling. Hypertension. 1996;28:505-506.
15. Virdis A, Savoia C, Grassi G, et al. Evaluation of microvascular structure in humans: a 'state-of-The-art' document of the working group on macrovascular and microvascular alterations of the Italian society of arterial hypertension. J Hypertens. 2014;32:2120-2129.
16. Virdis A, Colucci R, Fornai M, et al. Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: role of inducible nitric-oxide synthase and oxidative stress. J Pharmacol Exp Ther. 2005;312:945-953.
17. Rizzoni D, Porteri E, Castellano M, et al. Endothelial dysfunction in hypertension is independent from the etiology and from vascular structure. Hypertension. 1998;31:335-341.
18. Endemann DH, Pu Q, De Ciuceis C, et al. Persistent remodeling of resistance arteries in type 2 diabetic patients on antihypertensive treatment. Hypertension. 2004;43:399-404.
19. Rizzoni D, Porteri E, De Ciuceis C, et al. Lack of prognostic role of endothelial dysfunction in subcutaneous small resistance arteries of hypertensive patients. J Hypertens. 2006;24:867-873.
20. Luscher TF. Endogenous and exogenous nitrates and their role in myocardial ischaemia. Br J Clin Pharmacol. 1992;34(suppl 1):29S-35S.
21. Cardillo C, Kilcoyne CM, Cannon RO, et al. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension. 2000;35:1237-1241.
22. Dhaun N, Goddard J, Kohan DE, et al. Role of endothelin-1 in clinical hypertension: 20 years on. Hypertension. 2008;52:452-459.
23. Schiffrin EL. State-of-The-art lecture. Role of endothelin-1 in hypertension. Hypertension. 1999;34:876-881.
24. Taddei S, Virdis A, Ghiadoni L, et al. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation. 1999;100:1680-1683.
25. Vanhoutte PM. Endothelium and control of vascular function. State of the art lecture. Hypertension. 1989;13:658-667.
26. Vanhoutte PM, Tang EH. Endothelium-dependent contractions: when a good guy turns bad! J Physiol. 2008;586:5295-5304.
27. Yang D, Feletou M, Boulanger CM, et al. Oxygen-derived free radicals mediate endothelium-dependent contractions to acetylcholine in aortas from spontaneously hypertensive rats. Br J Pharmacol. 2002; 136:104-110.
28. Virdis A, Colucci R, Fornai M, et al. Cyclooxygenase-1 is involved in endothelial dysfunction of mesenteric small arteries from angiotensin iiinfused mice. Hypertension. 2007;49:679-686.
29. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension. 2004;44:248-252.
30. Taddei S, Virdis A, Mattei P, et al. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929-933.
31. Taddei S, Virdis A, Ghiadoni L, et al. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension. 1997;29: 274-279.
32. Taddei S, Virdis A, Ghiadoni L, et al. Vitamin c improves endotheliumdependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation. 1998;97:2222-2229.
33. Egashira K, Inou T, Hirooka Y, et al. Effects of age on endotheliumdependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation. 1993;88:77-81.
34. Zeiher AM, Drexler H, Saurbier B, et al. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest. 1993;92:652-662.
35. Taddei S, Virdis A, Mattei P, et al. Hypertension causes premature aging of endothelial function in humans. Hypertension. 1997;29:736-743.
36. Taddei S, Virdis A, Mattei P, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation. 1995;91:1981-1987.
37. Taddei S, Virdis A, Ghiadoni L, et al. Age-related reduction of no availability and oxidative stress in humans. Hypertension. 2001;38:274-279.
38. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56: 387-437.
39. Feletou M, Huang Y, Vanhoutte PM. Endothelium-mediated control of vascular tone: cox-1 and cox-2 products. Br J Pharmacol. 2011;164: 894-912.
40. Virdis A, Bacca A, Colucci R, et al. Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase-2 in oxidative stress generation. Hypertension. 2013;62:337-344.
41. Vanhoutte PM. One or two, does it matter as long as the arterial wall is coxygenated? Hypertension. 2013;62:244-246.
42. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormonereleasing acylated peptide from stomach. Nature. 1999;402:656-660.
43. Otto B, Spranger J, Benoit SC, et al. The many faces of ghrelin: new perspectives for nutrition research? Br J Nutr. 2005;93:765-771.
44. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908-913.
45. Kleinz MJ, Maguire JJ, Skepper JN, et al. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man. Cardiovasc Res. 2006;69: 227-235.
46. Iglesias MJ, Pineiro R, Blanco M, et al. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res. 2004;62:481-488.
47. Iantorno M, Chen H, Kim JA, et al. Ghrelin has novel vascular actions that mimic pi 3-kinase-dependent actions of insulin to stimulate production of no from endothelial cells. Am J Physiol Endocrinol Metab. 2007; 292:E756-E764.
48. Kawczynska-Drozdz A, Olszanecki R, Jawien J, et al. Ghrelin inhibits vascular superoxide production in spontaneously hypertensive rats. Am J Hypertens. 2006;19:764-767.
49. Tesauro M, Schinzari F, Iantorno M, et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation. 2005;112: 2986-2992.
50. Tesauro M, Schinzari F, Rovella V, et al. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension. 2009;54:995-1000.
51. Virdis A, Duranti E, Colucci R, et al. Ghrelin restores nitric oxide availability in resistance circulation of essential hypertensive patients: role of nad(p)h oxidase. Eur Heart J. 2015;36:3023-3030.